Privia Health Exceeds 2025 Guidance, Projects Strong 2026 Growth with ~20% Adjusted EBITDA Increase

summarizeSummary

Privia Health Group announced strong fourth quarter and full-year 2025 financial results, exceeding its own guidance ranges for the year, and provided an optimistic outlook for 2026 with projected double-digit Adjusted EBITDA growth.

check_boxKey Events

• Full-Year 2025 Results Exceed Guidance

  Privia Health reported full-year 2025 financial and operating metrics at or above the high end of its guidance ranges, including a 22.3% increase in total revenue to $2.12 billion and a 38.8% rise in Adjusted EBITDA to $125.5 million.

• Significant Profitability and Cash Flow Growth

  Net income for full-year 2025 surged by 59.3% to $22.9 million, while net cash provided by operating activities grew 49.5% to $163.4 million.

• Positive 2026 Financial Outlook

  The company issued 2026 guidance projecting continued growth, with Adjusted EBITDA expected to increase by approximately 15.5% to 23.5% (midpoint ~20%) to a range of $145 million to $155 million.

• Robust Balance Sheet

  Privia Health ended 2025 with a strong cash balance of $479.7 million and no debt, with expectations to reach approximately $600 million in cash by the end of 2026.

auto_awesomeAnalysis

Privia Health's latest earnings report signals robust operational and financial health, significantly outperforming its own high-end guidance for 2025 across key metrics like Adjusted EBITDA, net income, and attributed lives. This strong performance, coupled with a healthy balance sheet featuring substantial cash and no debt, provides a solid foundation for future growth. The positive 2026 guidance, projecting continued double-digit Adjusted EBITDA growth, reinforces investor confidence in the company's ability to execute its strategy and expand its physician enablement platform. Investors should view this report as a strong indicator of sustained operational momentum and financial stability.